News Communiqué II
Download the PDF Authorised for ASX release by the Board of Directors...
Read MoreInvestor Presentation - NYC Nasdaq Event
CLINUVEL hosted a Rendez-Vous evening event at the Nasdaq in New York...
Read MoreFirst stroke patient treated with PRÉNUMBRA® Instant
CLINUVEL has started its second stroke trial (CUV803) with the first patient...
Read MoreTechnical note: Arterial Ischaemic Stroke (AIS)
This Technical Note provides further detail on the current standards of care...
Read MoreDNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read MoreStatement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreNews Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read MoreCommercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read MoreRelief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCYACÊLLE Polychromatic Solar Care – λ3
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreProposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreGlobal SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreAppendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More